These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22020213)

  • 41. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF; Kane SE; Sonenshein GE
    Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].
    Ma F; Xu BH; Li HH; Li Q; Zhang P; Yuan P; Wang JY; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):521-4. PubMed ID: 24257305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
    Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual blockade of HER2 - twice as good or twice as toxic?
    Fralick M; Hilton JF; Bouganim N; Clemons M; Amir E
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):593-603. PubMed ID: 22748560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
    Somlo G; Martel CL; Lau SK; Frankel P; Ruel C; Gu L; Hurria A; Chung C; Luu T; Morgan R; Leong L; Koczywas M; McNamara M; Russell CA; Kane SE
    Breast Cancer Res Treat; 2012 Feb; 131(3):899-906. PubMed ID: 22042372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
    Bates M; Sperinde J; Köstler WJ; Ali SM; Leitzel K; Fuchs EM; Paquet A; Lie Y; Sherwood T; Horvat R; Singer CF; Winslow J; Weidler JM; Huang W; Lipton A
    Ann Oncol; 2011 Sep; 22(9):2014-2020. PubMed ID: 21289364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.
    Rowe DL; Ozbay T; Bender LM; Nahta R
    Mol Cancer Ther; 2008 Jul; 7(7):1900-8. PubMed ID: 18645000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resistance to trastuzumab: a necessary evil or a temporary challenge?
    Cardoso F; Piccart MJ; Durbecq V; Di Leo A
    Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.